Oncotelic Therapeutics, Inc. OTLC
Set alert
At close · Oct 30
- YTD
- -75.00%
- 1 year
- -80.00%
- Open
- 0.0185
- Prev close
- 0.02
- Mkt cap
- 9.15M
- Vol
- 175.69K
- Avg vol
- 337.13K
- EPS
- 0.59
- P/E
- 0.03
More statistics
- Low
- 0.0165
- High
- 0.025
- Earnings
- Aug 18, 2023
News
6 days ago globenewswire.com
Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature
Study combines AI-guided literature investigation with gene-expression analysis to identify a four-gene signature for Sapu003 development
1 week ago globenewswire.com
Oncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled Discovery
Saran Saund to connect the emerging research approach with PDAOAI intellectual property, plans for 100 billion biological vectors, individual researcher access through Fastbot/Membot and an HCC case…
3 weeks ago globenewswire.com
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
Oncotelic's AI drug discovery platform invites scientists, developers and biotech founders to connect computational discovery with drug development. Source: Oncotelic Therapeutics, Inc. AGOURA HILLS,…
3 months ago globenewswire.com
Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as…
3 months ago globenewswire.com
Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)
AGOURA HILLS, Calif. , July 22, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano today announced the publication of a comprehensive peer-reviewed study in…
3 months ago globenewswire.com
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
Clinical Program Advances Following Favorable Safety Review; Peer-Reviewed Publication Further Validates Deciparticle Platform SAN DIEGO, Calif. , July 07, 2026 (GLOBE NEWSWIRE) -- Oncotelic (OTCQB:…
4 months ago globenewswire.com
Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003
Publication Highlights Novel Intravenous Everolimus Formulation and Demonstrates Broad Potential of Deciparticle ™ Technology for Hydrophobic Therapeutics
4 months ago globenewswire.com
Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026
Company to Showcase Integration of AI, Digital Batch Records, and Intelligent Robotics to Accelerate Pharmaceutical Manufacturing AGOURA HILLS, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Oncotelic…
4 months ago globenewswire.com
Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services
SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB: OTLC) today announced the completion of key Phase 2 objectives in its joint…
4 months ago globenewswire.com
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies
AUSTIN, Texas, June 05, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “How Advanced Drug Delivery Could Improve Existing Cancer Treatments,”…
5 months ago globenewswire.com
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands…
5 months ago globenewswire.com
Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
SAN DIEGO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Sapu Nano and Oncotelic Therapeutics (OTCQB:OTLC) today announced the expansion of its Phase 1b clinical development program for Sapu003…
5 months ago globenewswire.com
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- via BioMedWire - Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75brands…
5 months ago globenewswire.com
TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics
Deployment of the Company's LIM-E autonomous laboratory support robot completes Phase 1 objectives under the joint development agreement and establishes a foundation for future pharmaceutical…
5 months ago globenewswire.com
Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress
Agoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology,…
5 months ago globenewswire.com
NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations
AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market…
5 months ago globenewswire.com
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands…